ABOUT
Antagonist screening assay for ICOS/ICOS-L axis
InvivoGen offers a cellular assay specifically designed for screening antibody-, Fc-fusion protein-, or small-molecule antagonists of the ICOS/ICOS-L immune checkpoint (IC) axis. This assay is comprised of:
- Jurkat-Lucia™ hICOS: Reporter T cells
- Raji-hICOS-L: Antigen-presenting cells (APCs)
These paired cell lines allow the mimicking of the immune synapse between T cells and APCs through the interaction of cell surface molecules delivering T-cell activation signals.
Inducible Co-stimulator (ICOS, CD278) is an immunostimulatory IC and a member of the CD28 superfamily. Expression of ICOS is rapidly induced in CD4 and CD8 T cells upon their activation, whereas its ligand ICOS-L (CD275), is mostly expressed by APCs [1].
Assay principle:
This assay relies on the co-culture of Jurkat-Lucia™ hICOS and Raji-hICOS-L cells:
– Jurkat-Lucia™-ICOS cells express a hICOS-CD3ζ fusion protein along with the Lucia luciferase reporter gene under the control of an ISG54 minimal promoter fused to six NFAT response elements. CD3ζ is a key component of the T-cell receptor (TCR) and CD3 complex that triggers TCR downstream signaling.
– Raji-hICOS-L cells express the ICOS-L activating IC ligand.
In the presence of a potent ICOS or ICOS-L antagonist, the ICOS-CD3ζ-mediated activation is blocked and there is no Lucia production. Activation of the reporter T cells can be readily measured using QUANTI-Luc™ 4 Lucia/Gaussia detection reagent (see Figures).
T-cell key features:
- Stable hICOS-CD3ζ expression
- NFAT-inducible Lucia luciferase reporter activity
APC key features:
- Stable hICOS-L overexpression
InvivoGen also offers Jurkat-Lucia™ hICOS cells without Raji-hICOS-L cells to measure the potency of agonists of the ICOS/ICOS-L axis.
Read our review on Immune Checkpoint Blockade
Learn more about Immune Checkpoint Antibodies.
Reference:
1. Amatore, F. et al. 2020. Role of ICOS in cancer immunotherapy. Expert Opin Biol Ther 20, 141-150.
Disclaimer: These cells are for internal research use only and are covered by a Limited Use License (See Terms and Conditions). Additional rights may be available.
SPECIFICATIONS
Specifications
ICOS/ICOS-L
Human
Screening of antibody-based inhibitors of the ICOS/ICOS-L axis
Complete IMDM (see TDS)
Verified using Plasmotest™
- Human ICOS and ICOS-L expression have been verified by flow-cytometry.
- Reporter activity has been validated following the co-culture of the two cell lines.
- The stability for 20 passages following thawing has been verified.
- Both cell lines are guaranteed mycoplasma-free.
CONTENTS
Contents
-
Product:ICOS/ICOS-L Bio-IC™
-
Cat code:rajkt-hicos
-
Quantity:3-7 x 10^6 cells (x2)
- 1 vial of Jurkat-Lucia™ hICOS cells
- 1 vial of Raji-hICOS-L cells
- 1 ml of Blasticidin (10 mg/ml)
- 1 ml of Zeocin® (100 mg/ml)
- 1 tube of QUANTI-Luc™ 4 Reagent (sufficient to prepare 25 ml)
Please note: Both cell lines are sold together.
Shipping & Storage
- Shipping method: Dry ice
- Liquid nitrogen vapor
- Upon receipt, store immediately in liquid nitrogen vapor. Do not store cell vials at -80°C.
Storage:
Caution:
Details
Inducible Co-stimulator (ICOS, CD278) is an immunostimulatory IC and a member of the CD28 superfamily. Expression of ICOS is rapidly induced in CD4+ and CD8+ T cells upon their activation, whereas its ligand ICOS-L (also known as CD275), is mostly expressed by antigen-presenting cells [1]. The interaction between ICOS and ICOS-L delivers a secondary co-stimulatory signal through the activation of the transcription factor AKT, which promotes T cell proliferation and differentiation as well as the production of cytokines [1]. In tumor immunity, ICOS is involved in the amplification of the anti-tumor cytotoxic CD8+ T cell response, as well as the 'pro-tumor' function and maintenance of regulatory T cells (Tregs). Therefore, both agonistic and antagonistic monoclonal antibodies (mAbs) targeting this pathway are being investigated in combinational cancer immunotherapy [2]. Notably, ICOS agonistic mAbs have been shown to potentiate the effects of anti-CTLA-4 mAbs [3].
References:
1. Amatore, F. et al. 2020. Role of ICOS in cancer immunotherapy. Expert Opin Biol Ther 20, 141-150.
2. Solinas, C. et al. 2020. The rationale behind targeting the ICOS-ICOS ligand costimulatory pathway in cancer immunotherapy. ESMO Open 5.
3. Soldevilla, M.M. et al. 2019. ICOS Costimulation at the Tumor Site in Combination with CTLA-4 Blockade Therapy Elicits Strong Tumor Immunity. Mol Ther 27, 1878-1891.
DOCUMENTS
Documents
Technical Data Sheet
Validation Data Sheet
Safety Data Sheet
Certificate of analysis
Need a CoA ?
